Close Menu

NEW YORK (360Dx) – Roche's announcement last week at the American Association of Clinical Chemistry annual meeting that it is developing a mass spectrometry-based clinical analyzer gives the space both meaningful validation and a formidable new competitor.

Speaking to analysts at the AACC meeting, Jean-Claude Gottraux, head of Roche professional Dx said the company plans to develop a mass spec-based system with Hitachi, its collaborator on a number of other clinical instruments.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.